Advances in nano-delivery systems for overcoming the challenges of applying siRNA drugs in tumor therapy
Xiaoxin Yan , Jinhu Liu , Jie Liu , Suyun Wei , Ruixin Li , Weiwei Mu , Na Zhang , Yongjun Liu
Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) : 101119
Tumors pose a serious threat to human life and health. In recent years, gene therapy against tumors has garnered considerable attention. Small interfering RNAs (siRNAs), an important class of nucleic acid drugs, can silence the mRNAs of tumor-associated genes with high specificity through RNA interference (RNAi), inhibiting tumor-related signaling pathways or protein expression and thereby exerting anti-tumor effects. However, anti-tumor siRNA drugs are currently in the clinical research stage, and none of these drugs have been approved for marketing, mainly because of the challenges in terms of safety, efficacy and targeted delivery. Nano-delivery systems can enhance siRNA stability and improve siRNA pharmacokinetics and biodistribution, while increasing their uptake by target cells to achieve precise delivery and controlled release, thereby serving as a promising solution to overcome the challenges of siRNA drug application. This review summarizes the existing research on the nano-delivery systems currently available to help siRNAs achieve organ-targeted delivery and enhance the anti-tumor efficacy of siRNAs, discussing the characteristics of siRNA action and the unique advantages of different types of nano-delivery systems. The aim was to provide novel ideas for the design and optimization of siRNA-based drug delivery and the development of novel anti-tumor formulations to promote the clinical translation and application of siRNA drugs.
siRNA / Nano-delivery system / Tumor therapy / Organ-targeted delivery
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
Schambach A, Buchholz CJ, Torres-Ruiz R, Cichutek K, Morgan M, Trapani I, |
| [5] |
|
| [6] |
|
| [7] |
Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001; 409: 363-6. |
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
Shimizu T. RNA recognition in toll-like receptor signaling. Curr Opin Struct Biol 2024; 88: 102913. |
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, Guo J, |
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
|
| [79] |
|
| [80] |
|
| [81] |
|
| [82] |
Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood-brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther 2023; 8: 217. |
| [83] |
|
| [84] |
|
| [85] |
Cox TR. The matrix in cancer. Nat Rev Cancer 2021; 21: 217-38. |
| [86] |
|
| [87] |
Dowdy SF. Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol 2017; 35: 222-9. |
| [88] |
|
| [89] |
|
| [90] |
|
| [91] |
|
| [92] |
|
| [93] |
|
| [94] |
|
| [95] |
Crooke ST, Wang S, Vickers TA, Shen W, Liang XH. Cellular uptake and trafficking of antisense oligonucleotides. Nat Biotechnol 2017; 35: 230-7. |
| [96] |
|
| [97] |
|
| [98] |
|
| [99] |
|
| [100] |
|
| [101] |
Yamada K, Hildebrand S, |
| [102] |
|
| [103] |
|
| [104] |
|
| [105] |
|
| [106] |
|
| [107] |
|
| [108] |
Sun X, Setrerrahmane S, Li C, Hu J, Xu H. Nucleic acid drugs: recent progress and future perspectives. Signal Transduct Target Ther 2024;9:316. |
| [109] |
|
| [110] |
|
| [111] |
|
| [112] |
|
| [113] |
|
| [114] |
|
| [115] |
|
| [116] |
|
| [117] |
|
| [118] |
|
| [119] |
|
| [120] |
|
| [121] |
|
| [122] |
|
| [123] |
|
| [124] |
|
| [125] |
|
| [126] |
|
| [127] |
|
| [128] |
|
| [129] |
|
| [130] |
|
| [131] |
|
| [132] |
|
| [133] |
|
| [134] |
|
| [135] |
|
| [136] |
|
| [137] |
|
| [138] |
|
| [139] |
Song P, Wang B, Pan Q, Jiang T, Chen X, Zhang M, |
| [140] |
|
| [141] |
|
| [142] |
|
| [143] |
|
| [144] |
|
| [145] |
|
| [146] |
|
| [147] |
|
| [148] |
|
| [149] |
|
| [150] |
|
| [151] |
|
| [152] |
|
| [153] |
|
| [154] |
|
| [155] |
|
| [156] |
|
| [157] |
|
| [158] |
|
| [159] |
|
| [160] |
Motamedi H, |
| [161] |
|
| [162] |
|
| [163] |
|
| [164] |
|
| [165] |
|
| [166] |
|
| [167] |
|
| [168] |
|
| [169] |
|
| [170] |
|
| [171] |
Tang S, Tang D, Zhou H, Li Y, Zhou D, Peng X, |
| [172] |
|
| [173] |
|
| [174] |
Suzuki Y, Katsurada Y, |
| [175] |
|
| [176] |
|
| [177] |
|
| [178] |
|
| [179] |
Unterweger H, Janko C, Folk T, Cicha I, Kovács N, Gyebnár G, |
| [180] |
Oh JY, Villaseñor KE, Kian AC, Cormode DP. Advances in ultrasmall inorganic nanoparticles for nanomedicine: from diagnosis to therapeutics. ACS Appl Mater Interfaces 2025; 17: 28982-9001. |
| [181] |
|
| [182] |
|
| [183] |
|
| [184] |
|
| [185] |
|
| [186] |
|
| [187] |
|
| [188] |
|
| [189] |
|
| [190] |
|
| [191] |
|
| [192] |
|
| [193] |
|
| [194] |
|
| [195] |
|
| [196] |
|
| [197] |
|
| [198] |
|
| [199] |
|
| [200] |
Kim M, |
| [201] |
|
| [202] |
|
| [203] |
|
| [204] |
|
| [205] |
|
| [206] |
|
| [207] |
|
| [208] |
Kwak G, |
| [209] |
|
| [210] |
|
| [211] |
|
| [212] |
|
| [213] |
|
| [214] |
|
| [215] |
|
| [216] |
|
| [217] |
|
| [218] |
|
| [219] |
|
| [220] |
|
| [221] |
|
| [222] |
|
| [223] |
|
| [224] |
Xu X, Li S, Yu W, Yao S, Fan H, |
| [225] |
|
| [226] |
|
| [227] |
|
| [228] |
|
| [229] |
|
| [230] |
|
| [231] |
|
| [232] |
|
| [233] |
Kwak G, |
| [234] |
|
| [235] |
|
| [236] |
|
| [237] |
|
| [238] |
|
| [239] |
|
| [240] |
|
| [241] |
|
| [242] |
|
| [243] |
|
| [244] |
|
| [245] |
|
| [246] |
|
| [247] |
|
| [248] |
|
| [249] |
Buying time for transplants. Nat Biotechnol 2017; 35: 801. doi: 10.1038/nbt.3971. |
| [250] |
|
| [251] |
|
| [252] |
|
| [253] |
|
| [254] |
|
/
| 〈 |
|
〉 |